Karagiannakis DS. Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease: High Hopes and Ongoing Challenges. 2025.

Tsitsou S, Bali T, Adamantou M, Saridaki A, Poulia K-A, Karagiannakis DS, Papakonstantinou E, Cholongitas E. Effects of a 12-Week Mediterranean-Type Time-Restricted Feeding Protocol in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial—The ‘CHRONO-NAFLD Project’. Alimentary Pharmacology & Therapeutics. 2025;61:1290–1309.

Tsitsou S, Adamantou M, Bali T, Saridaki A, Poulia K-A, Karagiannakis DS, Papakonstantinou E, Cholongitas E. Chrononutrition and MASLD—It is About Time (Restricted Feeding)! Authors' Reply. Alimentary Pharmacology & Therapeutics. 2025;61:1567–1568.

Tsitsou S, Adamantou M, Bali T, Saridaki A, Poulia K-A, Karagiannakis DS, Papakonstantinou E, Cholongitas E. Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time-Restricted Feeding in MASLD Management—Authors' Reply. Alimentary Pharmacology & Therapeutics. 2025.

Papatheodoridi M, Sevastianos V, Zachou K, Christodoulou D, Koskinas I, Deutsch M, Alexopoulou A, Elefsiniotis I, Triantos C, Gigi E, et al. WED-304 HERACLIS\_BLV\_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D. Journal of Hepatology. 2025;82:S819–S820.

Papatheodoridi M, Paraskevopoulou S, Ioannidou P, Fytili P, Karagiannakis D, Cholongitas E, Vlachogiannakos I, Papatheodoridis G. SAT-300 The effect of antiviral therapy on the outcomes of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-). Journal of Hepatology. 2025;82:S800.